| blarcamesine (Anavex 2-73) / Anavex |
NCT03790709: ANAVEX2-73 for Treatment of Early Alzheimer's Disease |
|
|
| Completed | 2b | 509 | Europe, Canada, RoW | High dose ANAVEX2-73, Mid dose ANAVEX2-73, Placebo oral capsule | Anavex Life Sciences Corp., Anavex Australia Pty Ltd., Anavex Germany GmbH, Anavex Canada Ltd. | Alzheimer Disease | 06/22 | 06/22 | | |
| Active, not recruiting | 2b | 450 | Europe, Canada, RoW | ANAVEX2-73, Blarcamesine | Anavex Life Sciences Corp., Anavex Australia Pty Ltd., Anavex Germany GmbH | Alzheimer Disease | 07/24 | 07/24 | | |
ANAVEX, NCT02244541: Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of 2-73 in Patients With Alzheimer's Disease |
|
|
| Completed | 2a | 32 | RoW | ANAVEX2-73 Oral, ANAVEX2-73 Intravenous | Anavex Life Sciences Corp. | Alzheimer's Disease | 11/15 | 11/16 | | |
|
|
|
|
|
|
| Completed | 2 | 132 | Europe, RoW | High dose ANAVEX2-73, Mid dose ANAVEX2-73, Placebo oral capsule | Anavex Life Sciences Corp., Anavex Germany GmbH | Parkinsons Disease With Dementia | 09/20 | 09/20 | | |
NCT03758924: Study of ANAVEX2-73 in Patients With Rett Syndrome |
|
|
| Completed | 2 | 31 | US | ANAVEX2-73, Placebo | Anavex Life Sciences Corp., International Rett Syndrome Foundation Rettsyndrome.org | Rett Syndrome | 10/20 | 10/20 | | |
NCT02756858: An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease |
|
|
| Completed | 2 | 21 | RoW | ANAVEX2-73 | Anavex Life Sciences Corp. | Alzheimer's Disease | 11/20 | 11/20 | | |
| Completed | 2 | 132 | Europe, RoW | ANAVEX2-73, Blarcamesine | Anavex Life Sciences Corp., Anavex Australia Pty Ltd., Anavex Germany GmbH | Parkinson Disease Dementia | 05/22 | 06/22 | | |
